Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Zeteletinib adipate by Boston Pharmaceuticals for Medullary Thyroid Cancer: Likelihood of Approval
Zeteletinib adipate is under clinical development by Boston Pharmaceuticals and currently in Phase I for Medullary Thyroid Cancer. According to...